FILING ANALYSIS · FRIDAY, NOVEMBER 13
MetaVia Inc. MTVA — 8-K: Results of Operations and Financial Condition
positive
MetaVia Inc. reported positive interim data from its Phase 1 Part 3B study of DA-1726, showing a 68.1% placebo-adjusted reduction in liver fat, and announced plans for a Phase 2 study in MetALD and ALD. The company also appointed a new Chief Medical Officer, Sarah Browne, M.D., to lead the next stage of clinical development.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →